Timothy Erick, PhD
@DrTimothyErick
Senior Science Writer, Breast Oncology Center, Dana-Farber Cancer Institute. Views expressed are my own.
ID:2167103556
31-10-2013 19:07:49
8,1K Tweets
810 Followers
1,7K Following
Alarming how we're at risk of reversing 60+ years of public health progress and losing thousands of children's lives to measles in just the next 5 years. Let's prioritize vaccination and public health measures to prevent this devastating setback. #VaccinesSaveLives #PublicHealth
The Dana-Farber IBC program led by Filipa Lynce, MD, FASCO is outstanding and has clinical trials specific for IBC open for all subtypes of disease.
#RareDiseaseDay
Dana-Farber’s Breast Oncology Center OncoAlert #bcsm
On #RareDiseaseDay , let's spotlight the ETHAN trial, which will inform how we treat #MaleBreastCancer . Let's rally behind initiatives like these, paving the way for brighter futures.
Dana-Farber’s Breast Oncology Center OncoAlert #bcsm
We are thrilled to see our IBC clinical trial study is officially out in BreastCancerResearch. We found the use JAK1/2 inhibitor Ruxolitinib in TN-IBC resulted in decreased pSTAT3 but lack of clinical benefits. Comb with immunotherapy may need to be considered.
…ast-cancer-research.biomedcentral.com/articles/10.11…
Congrats to Filipa Lynce, MD, FASCO Polyak Lab Sara Tolaney Tari King MD Dr. E Mittendorf Meredith Regan, ScD jennifer bellon and co-authors on this excellent publication!
5-year update from #monarchE now published on Journal of Clinical Oncology. Impressive benefit with adjuvant abemaciclib in high-risk, node positive, HR+ breast cancer, with ~7% delta in distant relapse free survival. OS still immature, but trending in favor of abema. ascopubs.org/doi/pdf/10.120…